Lilly Pushes Buying Spree Beyond $32B With Calytrix Deal

Lilly Pushes Buying Spree Beyond $32B With Calytrix Deal

Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest in the drugmaker’s $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. Sam Fazeli, B...

Eli Lilly & Co. agreed to buy closely held Calytrix Bio Inc. in a deal that could be worth up to $1.5 billion, the latest in the drugmaker’s $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. Sam Fazeli, Bloomberg Intelligence, Director of Research for Global Industries and Senior Pharmaceuticals Analyst, discusses the biotech sector, how AI is playing a role in new developments and the importance of M&A through deals like that of Eli Lilly and Calytrix Bio. (Source: Bloomberg)
Lire l’article complet sur le site source
Bloomberg — Markets (EN)




Besoin d'un service ? Discutez maintenant !
🤖

Assistant eFastWork

En ligne

📩 Envoyer un message à notre équipe


ou envoyez un message vocal
👋

Bienvenue !

Entrez votre email pour commencer à chatter.

Email utilisé uniquement pour vous répondre.